Loading…

p38 Kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas

Inhibitors of the MAP kinase p38 are potentially useful for the treatment for osteoporosis, arthritis, and other inflammatory diseases. A series of thienyl, furyl, and pyrrolyl ureas has been identified as potent p38 inhibitors, displaying in vitro activity in the nanomolar range.

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry letters 2001-01, Vol.11 (1), p.9-12
Main Authors: Redman, Anikó M, Johnson, Jeffrey S, Dally, Robert, Swartz, Steve, Wild, Hanno, Paulsen, Holger, Caringal, Yolanda, Gunn, David, Renick, Joel, Osterhout, Martin, Kingery-Wood, Jill, Smith, Roger A, Lee, Wendy, Dumas, Jacques, Wilhelm, Scott M, Housley, Timothy J, Bhargava, Ajay, Ranges, Gerald E, Shrikhande, Alka, Young, Deborah, Bombara, Michael, Scott, William J
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inhibitors of the MAP kinase p38 are potentially useful for the treatment for osteoporosis, arthritis, and other inflammatory diseases. A series of thienyl, furyl, and pyrrolyl ureas has been identified as potent p38 inhibitors, displaying in vitro activity in the nanomolar range.
ISSN:0960-894X
1464-3405
DOI:10.1016/S0960-894X(00)00574-6